Hansen P E, Wang A G, Kragh-Sørensen P
Odense Universitetshospital, psykiatrisk afdeling.
Ugeskr Laeger. 1994 Nov 28;156(48):7224-8.
A total of 219 inpatients with a DSM-III diagnosis of major depression, (150 women and 69 men), were followed prospectively for three to ten years and mortality was recorded. The patients were previous participants in psychopharmacological multicentre trials, which were carried out for the purpose of comparing the antidepressant effect of newer selective serotonin reuptake inhibitors (SSRI), citalopram and paroxetine, with that of the tricyclic antidepressant drug, clomipramine. Diagnostic classification according to the Newcastle-I Scale into endogenous and nonendogenous depression was performed. The observed mortality was significantly greater than that expected. The increased mortality was essentially due to suicides and mainly found among women. Patients scored as being nonendogenously depressed had a significantly higher suicide rate than endogenously depressed patients. The excess number of suicides in the nonendogenous group largely occurred within the first year of observation. No association was found between response to the antidepressant treatment in the trial and the suicide risk during the first three years of observation.
共有219名被诊断为重度抑郁症的住院患者（150名女性和69名男性）接受了为期三至十年的前瞻性随访，并记录了死亡率。这些患者曾参与过精神药理学多中心试验，该试验旨在比较新型选择性5-羟色胺再摄取抑制剂（SSRI）西酞普兰和帕罗西汀与三环类抗抑郁药氯米帕明的抗抑郁效果。根据纽卡斯尔-1量表将诊断分类为内源性和非内源性抑郁症。观察到的死亡率显著高于预期。死亡率增加主要是由于自杀，且主要发生在女性中。被评为非内源性抑郁症的患者自杀率显著高于内源性抑郁症患者。非内源性组中自杀人数过多主要发生在观察的第一年。在试验中对抗抑郁治疗的反应与观察的前三年中的自杀风险之间未发现关联。
